Artificial Intelligence and Benign Lesions of Vocal Folds Recognition

February 21, 2023 updated by: Marchese Maria Raffaella, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Artificial Intelligence for the Recognition of Benign Lesions of Vocal Folds From Audio Recordings

The development of Artificial Intelligence (AI), the evolution of voice technology, progresses in audio signal analysis, and natural language processing/understanding methods have opened the way to numerous potential applications of voice, such as the identification of vocal biomarkers for diagnosis, classification or to enhance clinical practice. More recently, researches focused on the role of the audio signal of the voice as a signature of the pathogenic process. Dysphonia indicates that some negative changes have occurred in the voice production. The overall prevalence of dysphonia is approximately 1% even if the actual rates may be higher depending on the population studied and the definition of the specific voice disorder. Voice health may be assessed by several acoustic parameters. The relationship between voice pathology and acoustic voice features has been clinically established and confirmed both quantitatively and subjectively by speech experts. The automatic systems are designed to determine whether the sample belongs to a healthy subject or a non-healthy subject. The exactness of acoustic parameters is linked to the features used to estimate them for speech noise identification. Current voice searches are mostly restricted to basic questions even if with broad perspectives. The literature on vocal biomarkers of specific vocal fold diseases is anecdotal and related to functional vocal fold disorders or rare movement disorders of the larynx . The most common causes of dysphonia are the Benign Lesions of the Vocal Fold (BLVF). Currently, videolaryngostroboscopy, although invasive, is the gold standard for the diagnosis of BLVF. However, it is invasive and expensive procedure. The novel ML algorithms have recently improved the classification accuracy of selected features in target variables when compared to more conventional procedures thanks to the ability to combine and analyze large data-sets of voice features. Even if the majority of studies focus on the diagnosis of a disorder where they differentiate between healthy and non-healthy subjects, the investigators believe that the more important task is frequently differential diagnosis between two or more diseases. Even though this is a challenging task, it is of crucial importance to move decision support to this level. The main aim of this research would be the study, development, and validation of ML algorithms to recognize the different BVLVFL from digital voice recordings.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The investigators will collect the audio recordings of dysphonic participants affected by BLVF. All voice samples will be divided into the following groups based on the endoscopic diagnosis: vocal fold cysts, Reinke's edema, nodules and polyps. The audio tracks will be obtained by asking to pronounce with usual voice intensity, pitch and quality the word /aiuole/ three times in a row. Voices will be acquired using a Shure model SM48 microphone (Evanston IL) positioned at an angle of 45° at a distance of 20 cm from the patient's mouth. The microphone saturation input will be fixed at 6/9 of CH1 and the environmental noise was <30 dB sound pressure level (SPL). The signals will be recorded in ".nvi" format with a high-definition audio-recorder Computerized Speech Lab, model 4300B, from Kay Elemetrics (Lincoln Park, NJ, USA) with a sampling rate of 50 kHz frequency and converted to ".wav" format. Each audio file will be anonymously labelled with gender and type of BLVF.

Analysis pipeline All the following analyses will be performed using MatLab R2019b, the MathWorks, Natick MA, USA. The analysis pipeline included signal pre-processing, features extraction, screening of the features, and model implementation.

Features extraction On the segmented signal, 66 different features in the time, frequency, and cepstral domain will be extracted. Then, seven statistical measures will be computed on the extracted features, namely: mean, standard deviation, skewness, kurtosis, 25th, 50th, and 75th percentiles. In addition, jitter, shimmer, and tilt of the power spectrum will be obtained from the whole unsegmented signal.

Features screening Features screening will be applied using biostatistical analyses on the whole dataset, to reduce the extended number of features to give as input to the classifier. Two statistical tests will be used to screen relevant features for the classification task: the one-way analysis of variance (ANOVA), when all the groups were normally distributed, and the Kruskal-Wallis test, otherwise. The groups' normality will be verified through the Kolmogorov-Smirnov test. For all the tests, a p-value <0.05 will be considered statistically significant.

A. Model implementation A non-linear Support Vector Machine (SVM) with a Gaussian kernel is the algorithm chosen for this research. The classification performance will be measured through the accuracy and the average F1-score. Both metrics will be provided for the description of the overall classification performances and those obtained on gender sub-groups.

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients affected by benign lesions of vocal fold

Description

Inclusion criteria:

  • Reinke's edema
  • cyst of the vocal fold
  • nodule of the vocal fold
  • polyp of the vocal fold

Exclusion criteria:

  • previous laryngeal or thyroid surgery
  • previous speech therapy
  • current pulmonary diseases
  • current gastroesophageal reflux
  • laryngeal movement disorder or recurrent laryngeal nerve paralysis
  • Non-native Italian speakers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
validation of ML algorithms to recognize the different BVFL
Time Frame: five years
The statistical measures computed on the extracted features are the following: mean, standard deviation, skewness, kurtosis, 25th, 50th, and 75th percentiles. In addition, jitter, shimmer, and tilt of the power spectrum will be obtained from the whole unsegmented signal.
five years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Anticipated)

November 1, 2025

Study Completion (Anticipated)

November 1, 2025

Study Registration Dates

First Submitted

February 1, 2023

First Submitted That Met QC Criteria

February 21, 2023

First Posted (Estimate)

March 6, 2023

Study Record Updates

Last Update Posted (Estimate)

March 6, 2023

Last Update Submitted That Met QC Criteria

February 21, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dysphonia

Clinical Trials on Audio recordings

Subscribe